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INTRODUCTION
Hepatic ischemia–reperfusion (I/R) is a key clinical problem 
associated with numerous adverse events such as hypovolemic 
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shock,[1] disseminated intravascular coagulation,[2] liver transplan-
tation and surgery,[3] cardiac failure and arrest, alcohol toxicity, 
and several other pathological conditions. The observed patho-
physiology of hepatic I/R injury is as follows. The liver is a highly 
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oxygen‑utilizing organ. Thus, impairment of blood flow rapidly 
causes hepatic hypoxia, which may progress to absolute anoxia, 
particularly in the pericentral regions of the hepatic lobe.
Subsequent reperfusion leads to the activation of Kupffer cells, 
which are resident macrophages of the liver. These cells contribute 
to liver pathology by producing reactive oxygen species (ROS) 
such as superoxides, hydrogen peroxide, and hydroxyl radicals, 
which have been implicated in cell damage. Oxidative stress 
can also promote lipid peroxidation, which causes structural and 
functional derangements and cell death ultimately.[4,5] In addition, 
pro‑inflammatory cytokines, chemokines, and other mediators 
produced by these cells contribute to post-ischemic tissue injury, 
systemic inflammatory syndrome, and multiorgan failure. In con-
junction with activated complement factors, these inflammatory 
mediators activate and recruit neutrophils into the post-ischemic 
liver, which generates excess of reactive oxygen radicals and 
releases additional proteases and other degradative enzymes.[6-9]
In addition to an inflammatory response, ROS induces the ex-
pression of endothelin-1 and consequent vasoconstriction of sinu-
soids. This promotes the heterogeneous closure of many microves-
sels and prolongs ischemia in certain areas of the liver even after 
reperfusion.[5,10] Therefore, finding appropriate treatments for 
hepatic I/R injury is of paramount importance.
N-acetylcysteine (NAC) is a small molecule containing a 
thiol (sulfhydryl-containing) group, which has antioxidant proper-
ties and is freely filterable, thus making it readily accessible to the 
intracellular compartment.[11,12] NAC has been clinically used for 
more than 30 years, primarily as a mucolytic agent. It has also been 
used in states of decreased glutathione (GSH) and oxidative stress 
in HIV infections, cancer, heart diseases, and other diseases. Due to 
its hepatoprotective activity, intravenous and oral administrations 
of NAC have been used extensively for the treatment of acetamino-
phen poisoning. The diverse pharmacological applications of NAC 
are mainly due to its physiological role as an ROS scavenger.[12,13]
Prostaglandin E1 (PGE1) is a naturally occurring prostaglan-
din. It was originally introduced as a therapeutic agent because 
of its potent direct vasodilator actions. Numerous experiments 
indicate a beneficial effect of PGE1 when intravenously admin-
istered to patients with chronic vascular disease due to its pos-
sible direct vasodilatory effect causing an increase in local tissue 
perfusion.[14] Alprostadil is a synthetic form of PGE1 that can 
function as a PGE1 analog by producing a strong relaxant effect 
on the smooth muscles of peripheral blood vessels. It functions 
as a peripheral vasodilator and platelet aggregation inhibitor by 
interacting with specific G‑protein coupled receptors to increase 
the adenosine levels in plasma. Adenosine is an endogenous by-
product of purine metabolism that causes vasodilation, decreases 
leukocyte activities, provides for endothelial protection, inhibits 
platelet aggregation, and ameliorates the rheological properties of 
blood with a concomitant increase in oxygen delivery to tissues.[15] 
Although alprostadil has been used for several years in patients 
with liver transplants,[16] the mechanisms related to its protective 
effects against hepatic I/R injury remain unknown.
In the present study, the protective effects of NAC and/or 
alprostadil against hepatic I/R-induced tissue damage in rats were 
examined by measuring different biochemical parameters. These 
included the levels of the following parameters: (1) an end prod-
uct of lipid peroxidation; (2) liver malondialdehyde (MDA); (3) 
antioxidant enzymes, including catalase (CAT), superoxide 
dismutase (SOD), and GSH; and (4) indicators of inflammation, 
including myeloperoxidase (MPO) activity and nitric oxide (NO).
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (250-300 g) were obtained from the 
animal center of the National Science Council, Taiwan, Republic 
of China. They were fed a standard diet and were given water 
ad libitum. They were treated according to the regulations in the 
“Guide for the Care and Use of Laboratory Animals” (National 
Academy Press, 1996). The use of animals for our experiments 
was approved by the ethics committee of the National Yang-Ming 
University, Taipei, Taiwan.
Thirty rats were randomly divided into five groups (six rats in 
each group) as follows: Control, I/R, I/R + NAC, I/R + alprostadil, 
and I/R + NAC + alprostadil groups. Rats in the control group were 
neither subjected to I/R injury nor any treatment. In the I/R groups 
with treatments, the rats were subjected to 60 min of hepatic isch-
emia followed by a 60-min reperfusion period. For the treatment 
groups, an infusion pump (KDS220; KD Scientific Co., Holliston, 
MA, USA) was used to infuse 150 mg/kg of NAC and/or 0.05 μg/
kg of alprostadil into the femoral vein continuously for 30 min prior 
to 60 min of hepatic ischemia followed by 60 min of reperfusion.
Animal model and parameters for hepatic I/R injury
The rat model with I/R injury was generated as previously de-
scribed.[17,18] Briefly, each male Sprague‑Dawley rat was anesthetized 
with urethane (1.25 g/kg, intraperitoneally) and its trachea was 
cannulated for artificial respiration with a ventilator. A polyethyl-
ene (PE-50) catheter was inserted into the femoral artery to monitor 
blood pressure using a polygraph (TA240S; Gould Co., USA) and 
for drug administration. The liver was exposed through an upper 
midline incision and two pieces of fine silk thread were looped 
along the right and left branches of the portal vein, hepatic artery, 
and bile duct. This procedure whereby the silk thread was inserted 
into a snare with a piece of PE-90 tubing provided for the occlu-
sion of the blood supply to the median and left lobes (left branch).
To study I/R injury, ischemia and reperfusion period (each 
maintained for 60 min) of the median/left lobes with immediate 
occlusion of the right lobe vasculature was carried out. One hour 
after completing the reperfusion procedure, the initial ischemic–re-
perfused median/left lobes were resected and determination of the 
levels of MPO, MDA, GSH, CAT, SOD, and NO was made. Blood 
samples for alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) measurements were collected immediately after 
femoral catheterization and completion of the reperfusion procedure.
Biochemical analyses
MPO assay
MPO activity in the liver tissue was determined using a pro-
cedure similar to that of Hillegas et al.[19] Harvested liver samples 
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were homogenized in 50 mM potassium phosphate buffer (PB, 
pH 6.0) and centrifuged at 41,400 × g for 10 min. The pellets 
were then suspended in 50 mM PB containing 0.5% hexadecyl 
trimethyl ammonium bromide. After three cycles of freezing and 
thawing, with sonication between each cycle, the samples were 
centrifuged at 41,400 × g for 10 min. An aliquot (0.3 ml) was 
added to 2.3 ml of a reaction mixture containing 50 mM PB, 
0.19 mg/ml o-dianisidine, and 20 mM H2O2 solution. Enzyme 
activity was defined as the amount of MPO that caused a change 
in the absorbance measured at 460 nm for 3 min. MPO activity 
was expressed as U/g tissue.
MDA assay
A liver sample (0.5 g) was homogenized in 4.5 ml of thio-
barbituric acid (TBA) reagent containing 0.375% TBA, 15% 
trichloroacetic acid, and 0.25 N HCl. Samples were boiled for 
15 min, cooled, and centrifuged. Absorbance of the supernatants 
was spectrophotometrically measured at 532 nm.[20]
GSH assay
Hepatic GSH levels were determined using a commercial GSH 
assay kit (Cayman Chemical Co., Ann Arbor, MI, USA). This 
assay uses a carefully optimized enzymatic recycling method in 
which glutathione reductase is used to quantify GSH. Liver tissue 
was first homogenized in 5‑10 ml of cold buffer [either 50 mM 
MES or phosphate, pH 6-7, containing 1 mM ethylenediamine-
tetraacetic acid (EDTA)] per gram of liver tissue and centrifuged 
at 10,000 × g for 15 min at 4°C, followed by deproteination with 
metaphosphoric acid. After adding triethanolamine solution, an 
assay cocktail [a mixture of MES buffer (11.25 ml), reconstituted 
cofactor mixture (0.45 ml), reconstituted enzyme mixture (2.1 ml), 
water (2.3 ml), and reconstituted 5,5′‑dithiobis (2‑nitrobenzoic 
acid) (0.45 ml)] was prepared and total GSH in each of the de-
proteinated samples was determined spectrophotometrically at 
405 or 414 nm.
CAT assay
CAT activity was determined using a commercial chemical 
CAT assay kit (Cayman Chemical Co.). This assay utilizes the 
peroxidative function of CAT to determine the enzyme activity. 
Liver tissue was homogenized in 5‑10 ml of cold buffer (50 mM 
potassium phosphate, pH 7.0, containing 1 mM EDTA) per gram 
of liver tissue and centrifuged at 10,000 × g for 15 min at 4°C. 
The sample was then mixed sequentially with hydrogen peroxide, 
potassium hydroxide, Purpald, and potassium periodate, and then 
read at 540 nm.
SOD assay
Hepatic SOD activity was determined using a commercial SOD 
assay kit (Cayman Chemical Co.). This assay utilizes a tetrazolium 
salt to detect superoxide radicals generated by xanthine oxidase and 
hypoxanthine. Liver tissue was homogenized in 5‑10 ml of cold 
buffer (20 mM HEPES buffer, pH 7.2, containing 1 mM EDTA, 
210 mM mannitol, and 70 mM sucrose) per gram of liver tissue and 
centrifuged at 1500 × g for 5 min at 4°C. The reaction was initiated 
by adding xanthine oxidase and incubated at room temperature for 
20 min, after which the absorbance was read at 450 nm.
NO assay
Hepatic NO activity was determined using a commercial ni-
trate/nitrite colorimetric assay kit (Cayman Chemical Co.). This 
assay measures the total nitrate/nitrite concentrations in a simple 
two‑step method. The first step involves the conversion of nitrate 
to nitrite by nitrate reductase. The second step uses Griess reagent 
that converts nitrites into deep purple azo compounds which can be 
measured photometrically to determine the concentration of NO2
−.
Histological analysis
Rats were sacrificed by decapitation and the livers were har-
vested. Small pieces of liver tissue were placed in a 10% (v/v) 
formalin solution and processed routinely by embedding them in 
paraffin. Tissue sections (4‑5 μm) were stained with hematoxylin 
and eosin and examined under a light microscope. Results were 
interpreted by pathologists.
Statistical analysis
Results are expressed as means ± standard errors of the 
mean (SEMs). The concentrations of MPO, MDA, GSH, CAT, 
SOD, NO, ALT, and AST in different experimental groups were 
compared using the Wilcoxon rank sum test. A P value of < 0.05 
indicated statistical significance.
RESULTS
Hepatic I/R induction and effects of NAC and/or alprostadil
During the experimental procedure, blood pressure was 
continuously monitored using a polygraph. The blood pressure 
of all experimental rats remained stable and none of them died 
during I/R induction. To evaluate the level of liver damage after 
the reperfusion procedure, blood samples from different groups 
were collected immediately via the femoral catheters after 
completing the reperfusion procedure. As shown in Table 1, the 
ALT and AST levels increased significantly in the I/R group as 
compared with the control group, while treatment with either 
NAC or alprostadil ameliorated these increases in ALT and AST. 
These results indicated that although the liver damage had been 
attenuated, there was no significant difference between combined 
treatment (NAC + alprostadil) and each treatment administered 
separately.
The antioxidant activity of NAC and/or alprostadil in the 
liver
Because antioxidant enzymes are important for maintaining 
an optimal chemical reducing environment to protect liver from 
ROS damage, we analyzed the activities of several of these liver 
enzymes. As shown in Figure 1a, CAT levels were decreased 
after I/R was induced, and the decrease was significantly 
lower than that in the control group. Treatment with NAC and 
NAC + alprostadil improved the CAT activity, while alprostadil 
alone had no effect on the CAT activity, compared with the I/R 
group. The level of hepatic SOD in the liver tissue also decreased 
after I/R induction, which was significantly lower in the control 
group. Compared with the I/R group, separate treatments with 
NAC and alprostadil and their combined administration clearly 
67
Hsieh, et al. / Journal of Traditional and Complementary Medicine 4 (2014) 64‑71
increased the SOD levels. However, there were no synergistic 
effects of the combined treatment as compared with the results 
of separate treatments [Figure 1b]. We also measured the levels 
of GSH, which participates in many metabolic processes that 
protect cells against the actions of free radicals. As shown in 
Figure 1c, hepatic GSH levels in the liver tissue decreased after 
I/R induction, which was significantly lower than in the control 
group. Compared with the I/R group, GSH levels were signifi-
cantly increased in the NAC group (226.9 ± 11.0 μM) and in the 
NAC + alprostadil group (202.1 ± 12.9 μM). The mean liver MDA 
level, an indicator of lipid peroxidation, was also estimated. The 
MDA value was significantly higher in the I/R group than in the 
control group. Compared with the I/R group, the mean MDA level 
was significantly decreased in the I/R + NAC group. However, 
there was no significant difference in the MDA levels in either 
the alprostadil group or the NAC + alprostadil group compared 
with the I/R group [Figure 1d].
The anti‑inflammatory effect of NAC and/or alprostadil in 
the liver
Because the inflammatory response after I/R plays a critical 
role in cell damage, we examined the hepatic MPO levels. This 
enzyme is reflective of tissue infiltration by neutrophils. As shown 
in Figure 2a, the mean hepatic MPO level in the I/R group was 
significantly increased in comparison to the control group. Interest-
ingly, the MPO level in the I/R group that received NAC treatment 
was lower compared with the I/R group (P < 0.05), whereas there 
were no significant changes in the MPO levels in the I/R/group 
treated with either alprostadil or NAC + alprostadil.
We also evaluated the levels of another indicator of inflamma-
tion, NO. As shown in Figure 2b, the NO levels in the collected 
liver tissue increased after I/R, and the increase was significantly 
higher than that in the control group. Compared with the I/R group, 
the liver NO levels were significantly lower in the I/R + NAC, 
I/R + alprostadil, and I/R + NAC + alprostadil groups.
Figure 1. Effects of ischemia–reperfusion (I/R) and pretreatment with NAC and/or alprostadil on (a) catalase, (b) superoxide dismutase, 
(c) glutathione, and (d) malondialdehyde levels in liver tissues. Procedures are described in Materials and Methods. *P < 0.05 as compared with 
the I/R group
dc
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HISTOLOGICAL RESULTS
In order to assess the physiological effects of these treatments 
in terms of liver protection, we examined liver histology after I/R 
induction. As shown in Figure 3, in the control group, normal liver 
parenchyma cells appeared with both hepatocytes and sinusoids 
around the central vein with a regular morphology. In the I/R group, 
hepatocytes were prominently swollen with marked vacuolization. 
Congestion was noted in enlarged sinusoids. The liver parenchyma 
cells accompanying both hepatocytes and sinusoids around the 
central vein showed abnormal morphology. In the I/R + NAC 
group, the I/R + alprostadil group, and the I/R + NAC + alprostadil 
group, hepatocytes and sinusoids exhibited normal morphology 
which indicated well-preserved liver parenchyma cells.
DISCUSSION
Hepatic I/R injury occurs in many clinical scenarios such as 
transplantation, trauma, and hepatectomy, and extensive research 
has been done to improve its clinical results. The aim of some stud-
ies was to restore the blood supply to the ischemic liver; however, 
this could lead to further damage.
This paradox has led to an uncertainty regarding the effec-
tiveness of these treatments. Because I/R injury has a complex 
pathophysiology that results from a number of contributing fac-
tors, it is difficult to achieve effective treatment or protection by 
targeting only individual mediators or mechanisms. During recent 
years, the most promising protective strategy against I/R injury to 
be explored is preconditioning. Preconditioned fasting, ischemia, 
pharmaceuticals, hyperosmolar solutions, and local somatothermal 
stimulation (LSTS) have appeared to increase the resistance of 
cells to ischemia and reperfusion events.[21-26]
The goal of this study was to analyze the combined effects of 
chemicals in preventing liver damage during hepatic I/R injury. For 
this study, we adopted a rat model that included the simultaneous 
occlusion of the right lobe vasculature along with reperfusion of 
the median/left lobes while making sure that the ischemic lobes 
were well reperfused. This was suggested to be a good model for 
Figure 3. Liver histological analysis. In the control group, normal liver 
parenchyma cells appear with hepatocytes and sinusoids around the 
central vein and show regular morphology. In the I/R group, hepatocytes 
are prominently swollen with marked vacuolization (*). Congestion (+) 
is noted in enlarged sinusoids. The liver parenchyma cells accompanied 
by hepatocytes and sinusoids around the central vein show irregular 
morphology. In the I/R + NAC group, the I/R + alprostadil group, and 
the I/R + NAC + alprostadil group, hepatocytes and sinusoids are present 
with normal morphology reflecting well‑preserved liver parenchyma cells. 
The scale bars represent 50 μm. (H and E, ×400)
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Figure 2. Effects of ischemia–reperfusion (I/R) and pretreatment with NAC and/or alprostadil on (a) myeloperoxidase and (b) nitric oxide levels in 
liver tissue. Procedures are described in Materials and Methods. *P < 0.05 as compared with the I/R group
ba
69
Hsieh, et al. / Journal of Traditional and Complementary Medicine 4 (2014) 64‑71
studying hepatic I/R injury.[17,18,27]
In this model, the time period of I/R is important. If the isch-
emia period is either too short (<20 min) or too long (>90 min), it 
would result in either minimal damage or irreversible structural 
and functional changes, respectively. Sinusoidal perfusion fail-
ure is aggravated when the ischemic time period is prolonged to 
60 min.[28] Using 60 min of median/left lobar ischemia followed 
by 60 min of reperfusion as a model, our results showed distinct 
functional alterations [Table 1]. In addition, this model provided 
a reproducible system for studying the protective effects of NAC 
and/or alprostadil on hepatocytes resulting from I/R injury.
NAC is known to counteract oxidative stress and replenish 
GSH levels. This drug has been shown to have antioxidant activ-
ity in vitro[29] and in vivo.[30,31] Nagasaki et al.,[32] showed that in a 
GSH-depleted liver, NAC prevented hepatic injury and improved 
its integrity after hepatic I/R injury, by acting not only as a substrate 
for GSH synthesis but also as a direct scavenger of free radicals. 
However, the evidence that NAC can reduce I/R injury and prevent 
complications after major surgery is not conclusive.
For example, in a randomized trial, Khan et al., found no 
significant difference between the control and NAC‑treated group 
in terms of peak serum transaminase levels and the pathological 
severity of I/R injury.[29,33] The present study demonstrated that 
NAC administration could improve liver functions and signifi-
cantly decrease I/R‑induced elevations of MPO, MDA, and NO 
activities while maintaining the levels of GSH, SOD, and CAT. 
Our histological findings also support the protective role of NAC 
toward the liver.
We determined the levels of several antioxidant indicators 
because oxygen-derived free radicals are widely known to be 
produced in many organs with I/R injury, such as the heart and 
liver. Recent evidence indicates that reactive oxygen metabolites 
play a fundamental role in the hepatotoxicity due to various 
xenobiotics and medications.[34-36] Lipid peroxidation is known 
to play an essential role in damaging the cell membrane through 
reactive oxygen radicals. I/R injury has been shown to increase 
MDA levels, which is an important index of lipid peroxidation.[37,38]
In addition, NO is synthesized by a family of enzymes desig-
nated as nitric oxide synthases (NOSs). Among these, the induc-
ible isoforms release NO in large amounts during inflammatory 
or immunologic reactions and are involved in host tissue damage 
responses. Superoxide anion is known to react with NO to produce 
peroxynitrite (ONOO−) that can readily modify proteins and other 
molecules.[39] Thus, apart from being an indicator of inflamma-
tion, NO can also interact with free radicals and cause further cell 
damage. In addition to NO, the enzyme MPO, which is restricted 
primarily to polymorphonuclear cells, can also serve as an indicator 
of inflammation and the generation of ROS because an increase 
in MPO activity reflects tissue neutrophil infiltration. MPO plays 
a fundamental role in oxidant production by neutrophils. Neu-
trophils are a potential source of oxygen free radicals[40] and are 
considered to be the major effector cells involved in tissue damage 
that occurs in several inflammatory diseases.[41,42] Previous stud-
ies have reported that the addition of neutrophils to the perfusate 
accentuated I/R injury in the isolated perfused kidney. Consistent 
with this, we observed a significant increase in the MPO activity 
in the liver tissue after hepatic I/R injury.
Mechanisms that have been proposed to explain I/R renal 
injury include anoxia followed by the release of oxygen-derived 
free radicals during reperfusion. It is reasonable to hypothesize 
that an increase in antioxidant enzyme levels, such as SOD and 
CAT, and the maintenance of GSH as well as the decrease in MDA 
and MPO levels due to NAC could ameliorate the liver damage 
due to I/R injury.
We also examined the protective effects of alprostadil, an 
analog of PGE1, against liver injury. Prostaglandins are released 
primarily by activated Kupffer cells during the reperfusion 
phase.[44] Several animal studies have shown that prostaglandins 
are effective for treating ischemic liver injury owing to their 
ability to increase liver perfusion, inhibit platelet aggregation, 
and also provide direct cytoprotection in a model of isolated 
perfused cat liver.[45] The protective actions of PGE1 may be 
related to its ability to reduce both the release of proteases and 
the generation of oxygen free radicals by activated leukocytes. 
Because of the synergistic role between platelets and leukocytes 
and the interaction of these cells with liver sinusoidal endothelial 
cells (LSECs) during the reperfusion phase,[46] it is conceivable 
that PGE1’s effects on leukocyte adherence may account for its 
favorable actions.
Greig et al., found that after reperfusion and progression to 
primary dysfunction, liver function could be restored by treat-
ment with PGE1.[47] However, the use of pharmacological doses 
of natural prostaglandins in clinical settings is limited because of 
drug-related side effects.[48] Thus, synthetic prostaglandin analogs 
have been developed which show milder side effects and longer 
half-lives.[48] Several of these analogs have actually improved 
animal survival and prevented parenchymal injury after prolonged 
periods of warm hepatic inflow occlusion.[49] In the current study, 
we observed that alprostadil could attenuate the production of NO 
induced by I/R and increase the amount of SOD. We expected that 
alprostadil could attenuate the infiltration of neutrophils. However, 
the value of MPO only increased slightly after the treatment of 
alprostadil, indicating its liver protection effect might come from 
pathways other than inhibiting the adhesion of neutrophils.
SOD activity and its amounts are decreased after I/R injury 
presumably via the inactivation of mature, active SOD within 
mitochondria.[50] Manson et al., were the first to demonstrate that 
the administration of SOD could enhance skin flap survival after 
arterial and venous occlusion.[51,52] Similarly, cardioplegic solutions 
containing SOD could enhance postoperative cardiac contractile 
Table 1. Effects of hepatic I/R injury and pretreatment with NAC 
and/or alprostadil on alanine aminotransferase and aspartate 
aminotransferase activities in plasma
Experimental groups ALT (U/l) AST (U/l)
Control 54.3±5.8 108.0±17.0
I/R 829.5±131.9* 1424.3±266.5*
I/R+NAC 375.3±62.6*,+ 448.8±109.0*,+
I/R+alprostadil 481.0±42.4*,+ 832.7±140.2*,+
I/R+NAC+alprostadil 318.2±113.2*,+ 588.1±171.7*,+
*P<0.05 as compared with the control group. +P<0. 0.05 as compared with 
the I/R group; ALT: Alprostadil; AST: Aspartate
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function after hypothermic global ischemia in dogs.[53]
In a study by Yang et al.,[54] NO had direct toxic effects on 
LSECs during hypoxia reoxygenation. First, NO production and the 
expression of eNOS and iNOS were increased in LSECs during hy-
poxia reoxygenation. Second, an NO inhibitor, N-ω-nitro-l-arginine, 
protected LSECs against apoptosis, while an NO activator, S-nitro-
so-N-acetylpenicillamine, increased LSEC apoptosis during hy-
poxia reoxygenation. Our results showing that NAC and alprostadil 
mediated inhibition of NO production were correlated with better 
clinical results, indicating a direct toxic role of NO in hepatic I/R 
injury. However, our results showed that treatment with both NAC 
and PGE1 was not synergistic. In our study, we have established 
that alprostadil is a less potent SOD inducer than NAC. Because 
NAC is a strong antioxidant, the antioxidative effect of alprostadil 
might not significantly improve the effect of NAC with regard to 
the reducing activity. Also, it is probable that alprostadil plays a 
role in downstream of the effect of NAC, such as ROS‑induced 
inflammation signaling; thus, no synergistic effect could be offered 
by alprostadil in combination of the treatment of NAC.
In summary, preconditioning with NAC and/or alprostadil 
treatments had a beneficial effect in protecting the rat liver 
against I/R injury. These protective effects provided by NAC or 
alprostadil are easily applied and may provide new avenues for 
the prevention of ischemic liver disease or problems that arise in 
liver transplantation.
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